Abstract
The administration of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) to pregnant women has been reported to cause ACEI/ARB fetopathy, including oligohydramios, pulmonary hypoplasia, renal insufficiency, limb contracture, and fetal hypotension in the child. Most of the patients die or develop end-stage renal failure during the neonatal period. The long-term prognosis of renal dysfunctions of patients with ARB fetopathy has not been reported. We report two pediatric cases, a 6- and 2-year-old boy, respectively, with ARB fetopathy whose renal functions were thoroughly evaluated after recovery from neonatal renal failure. Both patients showed (1) mildly decreased glomerular filtration rate, (2) no significant proximal tubular dysfunctions, and (3) salt-losing nephrogenic diabetes insipidus, while the excretion of arginine vasopressin and urine level of cyclic AMP were increased. The data on these two patients indicate that the administration of ARB to the fetus profoundly impairs the urine concentrating ability, probably due to papillary atrophy and the disturbed formation of the osmotic gradient in the medulla, which have been confirmed in neonatal rats administered with ACEIs or ARBs. ACEIs/ARBs must not be administered to pregnant women.
This is a preview of subscription content, log in via an institution to check access.
References
Guignard JP, Gouyon JB (1988) Adverse effects of drugs on the immature kidney. Biol Neonate 53:243–252
Pryde PG, Sedman AB, Nugent CE, Barr M Jr (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3:1575–1582
Shotan A, Widerhorn J, Hurst A, Elkayam U (1994) Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451–456
Schaefer C (2003) Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res 67:591–594
Kemper E (1992) ACE inhibitors. Available at: https://doi.org/www.fda.gov/bbs/topics/NEWS/NEW00270.html
Bowen ME, Ray WA, Arbogast PG, Ding H, Cooper WO (2008) Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 198:291
Guron G, Nilsson A, Nitescu N, Nielsen S, Sundelin B, Frokler J, Friberg P (1999) Mechanisms of impaired urinary concentrating ability in adult rats treated neonatally with enalapril. Acta Physiol Scand 165:103–112
Chen Y, Lasaitiene D, Gabrielsson BG, Carlsson LMS, Billig H, Carlsson B, Marcussen N, Sun XF, Friberg P (2004) Neonatal losartan treatment suppresses renal expression of molecules involved in cell-cell and cell-matrix interactions. J Am Soc Nephrol 15:1232–1243
Woods LL, Rasch R (1998) Perinatal ANG II programs adult blood pressure, glomerular number, and renal function in rats. Am J Physiol 275:R1593–1599
Lasaitiene D, Friberg P, Sundelin B, Chen Y (2004) Neonatal RAS inhibition changes the phenotype of the developing thick ascending limb of Henle. Am J Physiol Renal Physiol 286:F1144–F1153
Guron G, Molne J, Swerkersson S, Friberg P, Hansson S (2006) A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant 21:522–525
Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ (2007) Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 92:402–403
Sands JM, Bichet DG, American College of Physicians; American Physiological Society (2006) Nephrogenic diabetes insipidus. Ann Intern Med 7:186–194
Conflicts of interest:
none
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miura, K., Sekine, T., Iida, A. et al. Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker. Pediatr Nephrol 24, 1235–1238 (2009). https://doi.org/10.1007/s00467-008-1091-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-1091-8